NCT05704985 2025-05-29
Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors
DEKA Biosciences
Phase 1 Active not recruiting
DEKA Biosciences
Jiangsu Hansoh Pharmaceutical Co., Ltd.
ImmunityBio, Inc.
Jazz Pharmaceuticals
Eli Lilly and Company
Silverback Therapeutics